{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "CNMD",
  "name": "CONMED Corporation",
  "url": "https://frontierpicks.com/dossiers/CNMD/",
  "json_url": "https://frontierpicks.com/dossiers/CNMD.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Six weeks on, the deal leg is still the only unresolved one: no process headline since 2026-07-10, no sell-side action since 2026-07-30, no company event dated inside 30 days — yet price drifted to $51.07 on 2026-08-21, 10.9% above the $45.50 consensus average. Nothing arrives to price it until the review speaks or the ~late-October Q3 print lands.",
  "invalidation_trigger": "A weekly close below $46 surrenders the August shelf (closes of $49.12 on 2026-08-07 and $49.58 on 2026-08-11) and puts price back inside the published target stack; secondarily, an 8-K concluding the strategic review with no sale, or the ~2026-10-28 Q3 call passing with no dated process update.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "m-and-a-special-situations"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "The strategic-alternatives review reported 2026-07-10 has no company-confirmed timetable; the only dated marker in the story remains that report.",
    "The GI product-line exit completed early 2026 cut Q1 revenue ~$15.5M and dilutes FY2026 adjusted EPS by $0.45-0.50 - reported and organic growth diverge every quarter.",
    "Q2 adjusted EPS of $1.38 included a $0.21/share tariff refund that was not in guidance; year-over-year adjusted comparisons are distorted.",
    "CFO transition: John E. Gallagher effective 2026-07-15; predecessor Todd Garner remains an adviser until 2026-11-02.",
    "Vendor 52-week range ($31.44-$56.64) is intraday; the adjusted daily series used for levels here shows a 52-week high of $55.6.",
    "An idiosyncratic special situation in a surgical-device maker; sector medtech momentum tags do not describe what moves the stock."
  ],
  "body_markdown": "## Current Thesis\nNothing has entered this story since the last note. The last process headline is still dated 2026-07-10, the last sell-side action is still 2026-07-30, and the last company disclosure of substance is still the 2026-07-29 Q2 print. What has changed is the price: $49.58 on 2026-08-11, $51.07 at the 2026-08-21 close (-0.60% that session), 8.1% below the 52-week high of $55.6 on the adjusted daily series, with a three-month price change of +37.2% — essentially all of it earned in the two sessions after 2026-07-10.\n\nThe leg an investor is buying at this level is one item long and unchanged: an unresolved sale process, reported by media on 2026-07-10, with no company-confirmed timetable. Market cap is $1.53B on 29.95M shares and forward P/E 11.39; the consensus rating is Hold with an average target of $45.50, which stockanalysis.com marks as 10.9% below the 2026-08-21 close. Price is above every dated target on the tape, the highest being Wells Fargo's $46 from 2026-07-30.\n\n**The narrative is maturing, late.** The attention shock is dated (2026-07-10 report, 2026-07-13 movers lists). Fundamental confirmation is dated (2026-07-29). Sell-side follow-on was level adjustment without a rating change (Piper Sandler Neutral to $45, Wells Fargo Equal-Weight to $46, both 2026-07-30). Nothing has recruited a new holder since 2026-07-22, yet price made higher closes into 2026-08-21. The narrative still works and has stopped expanding.\n\n## Bull Case\n- **Organic growth is intact under the divestiture noise:** Q2 organic sales +6% YoY excluding the exited gastroenterology lines, General Surgery +5.3% organic, Orthopedics +6.8% organic (2026-07-29 call) — against reported sales of +0.3% and -0.5% constant currency.\n- **Guidance was raised, not reaffirmed, in the middle of a review:** FY2026 adjusted EPS to $4.48–$4.60 versus $4.34 consensus, FY sales narrowed to $1.358–$1.373B versus $1.362B consensus (2026-07-29). A board running a sale process raised the number it would be marketed on.\n- **Financeable size at a modest multiple:** $1.53B market cap on 29.95M shares, forward P/E 11.39 at the 2026-08-21 close (stockanalysis.com). JPMorgan commentary circulating 2026-07-13 argued the asset profile suits financial buyers over strategics.\n- **Robotic channel widened:** on 2026-07-22 CONMED said AirSeal is indicated for use with Intuitive's 8 mm hex cannulas on the da Vinci 5 platform, attaching the growth product to the largest installed robotic-surgery base.\n- **Price held the advance through six weeks of silence.** Between 2026-08-07 ($49.12) and 2026-08-21 ($51.07) the stock added ground with no news of any kind. Holders sitting on a +37.2% three-month move did not use the quiet to leave.\n\n## Bear Case\n- **A fifth of the beat was a refund:** the $1.38 adjusted figure included a $0.21-per-share tariff-refund benefit that was not in guidance (2026-07-29 call), and does not repeat in Q3.\n- **The growth product missed:** management said on 2026-07-29 that AirSeal growth was below expectations and second-half improvement would be slower than previously assumed. US orthopedics was roughly flat in the quarter.\n- **Price is through the entire published target stack:** BMO Market Perform $36 (2026-07-09), BofA Underperform $40 (2026-06-29), Piper Sandler $45 and Wells Fargo $46 (both 2026-07-30), consensus average $45.50 with a Hold rating (stockanalysis.com, 2026-08-21). No analyst has published a target consistent with $51.07 as a standalone value.\n- **The clock is the risk.** 42 days elapsed between the 2026-07-10 report and the 2026-08-21 close with no follow-up reporting, no 8-K, and no company statement on the review. Sale processes that are working usually leak a stage; this one has leaked nothing since it began.\n- **Nothing is scheduled that can resolve it.** There is no company event dated inside the next 30 days. The next fixed marker is the Q3 print, estimated late October.\n\n## Setup & Price Structure\nMeasured, from the adjusted daily series through 2026-08-21: last close $51.07, 52-week high $55.6, 8.1% below that high, RSI(14) at 45.5, three-month price change +37.2%. The vendor's own 52-week range reads $31.44–$56.64 on an intraday convention (stockanalysis.com, 2026-08-21).\n\nThe shape that matters: the stock gapped from a 2026-07-08 close of $33.59 on the 2026-07-10 report, ran to the $55–$56 area, then corrected. The August floor is visible in two closes — $49.12 on 2026-08-07 and $49.58 on 2026-08-11 — with price back in the upper half of that band at $51.07. RSI in the mid-40s while price sits within 8% of the high is the signature of a post-event range, not of a trending leg; momentum has bled off while the price level held.\n\nCrowding and positioning observables, stated as observables:\n- The $45.50 consensus average sits 10.9% below the 2026-08-21 close (stockanalysis.com). The gap between price and the target stack is the deal premium, and it is now wider than it was on 2026-08-11.\n- No sell-side target or rating action has been published since 2026-07-30 — 22 sessions of analyst silence into a rising price.\n- The 2026-08-14 13F deadline passed. Those filings report holdings as of 2026-06-30, before the 2026-07-10 report, so they cannot show event-driven or merger-arb accumulation. The Q3 round (deadline ~2026-11-14) is the first that can.\n- The only insider filing in the record since the process report is the 2026-07-15 grant to incoming CFO John E. Gallagher — with no dispositions disclosed. No issuance into strength has been reported.\n- There is no earnings date inside 30 days, which removes the usual forced-resolution point. Positioning can sit undisturbed until either the process speaks or late October arrives.\n\n## Catalyst Calendar (next 30 days)\n\n- **No company-scheduled event between 2026-08-23 and 2026-09-22.** No earnings date, no confirmed conference appearance found in CONMED's published events list as of 2026-08-23. The window is empty by the company's own calendar.\n- **~2026-10-28 (est.):** Q3 2026 results, the first print under CFO Gallagher. Outside the window; it is the next fixed date in the story.\n- **~2026-11-14:** Q3 13F deadline — the first filing round that reports post-2026-07-10 holdings.\n\n## Elapsed catalysts\n\n- **Undated, live since 2026-07-10:** any 8-K, press release or credible report on the strategic-alternatives review. This is the only item that can arrive inside the window, and it is not on a schedule. *(passed 47d ago)*\n\n## What Would Change Our Mind\nThe August shelf is what carries this. Two closes at $49.12 (2026-08-07) and $49.58 (2026-08-11) defined a floor that held through six weeks of no news; losing it on a weekly close below $46 would put price back inside the published target stack ($45.50 average, $46 top) and would mean the deal premium had been marked out without a headline to explain it. That is the gradeable break.\n\nTwo non-price conditions would do the same work more slowly. First, an 8-K or company statement concluding the review with a standalone plan: the premium above every dated target has no other support, and there is no second leg to fall back on. Second, the ~2026-10-28 Q3 call passing with no disclosed bidder, timetable or process language — a catalyst that comes and goes without resolving the one open item is itself the answer.\n\nOn the other side, a confirmed bidder or an agreed price ends the analysis in a single headline; so would a fresh report naming a stage of the process (second-round bids, financing commitments). The theme would flip to saturated if mainstream deal coverage arrives and price fails to hold the reaction day — a wide bid with no follow-through.\n\n## Correlation Notes\nSince 2026-07-10 this has traded on its own reporting, not on the medtech tape. The 2026-07-29 beat and raise did not produce a re-rating above the $55–$56 area reached earlier; price settled into the high-$40s/low-$50s and stayed there. Inference, not measurement: while a deal premium sits in the price, sector beta is suppressed, and a standalone conclusion would re-couple the name to medtech multiples and toward the $45.50 target stack.\n\nTwo live read-throughs. The 2026-07-22 AirSeal indication on the da Vinci 5 platform ties the growth line to Intuitive's installed base, so Intuitive's quarterly commentary on da Vinci 5 placements carries information about CONMED's second-half AirSeal recovery. Separately, the buyer thesis is a sponsor thesis — JPMorgan's 2026-07-13 commentary framed it that way — which makes leveraged-finance conditions, not medtech sentiment, the macro variable that matters to the premium.\n\nSector momentum tags do not describe what moves this stock. It is an idiosyncratic special situation in a surgical-device maker, and the distribution of outcomes is set by one process with no published timetable.",
  "first_seen": "2026-07-17",
  "last_analyzed": "2026-08-23T11:36:48+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}